Application No.: 10/009,791

Docket No.: BB-1356USPCT Page 7

AMENDMENTS TO DRAWINGS

Please replace the originally filed Figure 1 and Figure 2 with the attached amended figures. Corrections to the figure number necessitated amending the figures. Figure 1 is now Figure 1A, 1B and 1C. Figure 2 is now Figure 2A, 2B and 2C. No new matter has been added.

Attachment: Figures 1A, 1B and 1C

Figures 2A, 2B and 2C

Application No.: 10/009,791

Docket No.: BB-1356USPCT Page 8

REMARKS

Claims 1-20 have been cancelled without prejudice to or disclaimer of the subject matter recited therein.

Claims 21-33 have been added. Support for the reference to "coronatine-induced" in Claim 21 is found at least on page 1, lines 20-22, of the specification. Support for the sequence identities and the Clustal method recited in Claims 21-24 is found at least in the paragraph beginning on page 8, line 19 and continuing to page 9, line 2, of the specification. Support for Claims 25 and 26 is found at least in cancelled Claims 2-3. Support for the use of the term "recombinant" in Claims 28, 30, 31 and 32, is found at least in the paragraph at page 6, lines 14-16, of the specification. Support for Claims 27, 29, 31 and 32 are found at least in Examples 5-7, pages 25-29 of the specification. Support for Claim 33 is found at least in the original Claim 11. Thus, no new matter has been added.

The specification has been amended at two locations to remove reference to the following URL: www.ncbi.nlm.nih.gov/BLAST/.

Applicants submit herewith amended Drawings. The corrections to the figure numbering in the Drawings necessitated amending the specification to refer to this new figure numbering.

A Correction of Inventorship Under 37 C.F.R. 1.48(b), along with the requisite fee, is filed simultaneously herewith. This correction was necessitate by the Restriction Requirement.

RESPONSE TO RESTRICTION REQUIREMENT

Applicants hereby provisionally elect, without traverse, the subject matter of Group I, Claims 1-14 and 19, drawn to a polynucleotide, first method of making and first method of using said polynucleotide for further prosecution in the above-identified application. This election is made subject to Applicants' right to pursue the non-elected subject matter in a divisional application or applications pursuant to 35 USC §121.

Applicants further provisionally elect, without traverse, the subject matter of Invention K, SEQ ID NO:21 or a sequence encoding SEQ ID NO:22, wherein SEQ ID NO:22 is an amino acid sequence encoded by nucleotides 266-2086 of SEQ ID NO:21.

Applicants respectfully submit that now pending Claims 21-33 are directed to the subject matter of Group I and Invention K.

Application No.: 10/009,791

Docket No.: BB-1356USPCT Page 9

A Petition for Extension of Time of one (1) month up to and including April 19, 2004 (Monday), a request for Correction of Inventorship and the Corrected Drawings accompany the filing of this Preliminary Amendment and Response to Restriction Requirement.

Please charge any fees or credit any overpayment of fees which are required in connection with the filing of this Preliminary Amendment and Response to Restriction Requirement including, but not limited to, the Petition for Extension of time of one (1) month and Correction of Inventorship to Deposit Account No. 04-1928 (E. I. du Pont de Nemours and Company).

Allowance of the above-referenced application is respectfully requested in view of the foregoing.

Respectfully submitted,

Lynne M. Christonlury LYNNE M. CHRISTENBURY ATTORNEY FOR APPLICANTS REGISTRATION NO. 30,971

TELEPHONE: 302-992-5481 FACSIMILE: 302-892-1026

Dated: April 1, 2004